🇺🇸 FDA
Pipeline program

BCMA/CD19 Dual-Target CAR-T

PGC0008

Phase 1 mab active

Quick answer

BCMA/CD19 Dual-Target CAR-T for Multiple Myeloma is a Phase 1 program (mab) at Xijing Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Xijing Hospital
Indication
Multiple Myeloma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials